Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urothelial Carcinoma: early-phase trial registry
37 of 86 indexed Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #160 of 28,707 conditions by registered trial count.
86 US clinical trials · 37 currently recruiting · #160 of 28,707 conditions by registered trial count
Urothelial Carcinoma: 86 US clinical trials tracked, 37 recruiting.
Urothelial Carcinoma is the subject of 86 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is Fox Chase Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition urothelial-carcinoma
OPEN 37 | RECR 43% | LATE 6 | EARLY 59 | RANK #160 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Systemic Lupus Erythematosus (43% recruiting · 100 trials)
Urothelial Carcinoma lists 37 open slots (43% of 86 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urothelial Carcinoma is recruiting above its size-band peers.
37 of 86 indexed trials (43%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Urothelial Carcinoma trials is spread across many organizations.
Fox Chase Cancer Center accounts for 6 of 86 trials (7%). 63 distinct sponsors appear on at least one study for this condition label.
-
Typical Urothelial Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 86 trials that report a genuine target (sentinel values excluded). 50 of those (58.1%) plan for fewer than 100 participants.
-
Urothelial Carcinoma research is mostly interventional.
75 interventional and 11 observational studies make up this index (87.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
86 total, page 1 of 2
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Tampere University Hospital
NCT06310759
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
Pacific Edge Limited
NCT05889195
Bladder Cancer Screening Trial
University of Texas Southwestern Medical Center
NCT05646485
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
University of Texas Southwestern Medical Center
NCT04623502
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
UroGen Pharma
NCT05874921
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT04879329
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation
NCT04977453
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune
NCT06293898
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics
NCT07169734
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Dana-Farber Cancer Institute
NCT06138561
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences
NCT04969835
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
University of California, Davis
NCT06101290
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
University of Washington
NCT06040762
A Study of GEN1106 in Participants With Solid Tumors
Genmab
NCT07416123
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics
NCT06582017
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Case Comprehensive Cancer Center
NCT06262516
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
Fox Chase Cancer Center
NCT06396533
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT06332755
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
UroGen Pharma
NCT06774131
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Thomas Jefferson University
NCT07234968
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals
NCT06966024
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Noah Hahn, M.D.
NCT03317158
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
NCT07043972
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
NCT07390617
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
University of Michigan Rogel Cancer Center
NCT06356155
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
NCT07183319
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
NCT05868265
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT05239624
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
University of California, Irvine
NCT06682728
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Fox Chase Cancer Center
NCT03291028
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
Dana-Farber Cancer Institute
NCT06318871
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Mayo Clinic
NCT06339138
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT05911295
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology
NCT06111235
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Tyra Biosciences
NCT05544552
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma
NCT05243550
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
AbbVie
NCT06632951
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development
NCT03473743
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
University of Southern California
NCT02717156
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
UroGen Pharma
NCT06331299
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
Fox Chase Cancer Center
NCT02968732
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 22 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urothelial Carcinoma page
86 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fox Chase Cancer Center sponsors the most Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See Fox Chase Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Carcinoma condition card totals 86 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.